3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Recurrence
2
Burkitt Lymphoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasm, Residual
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Interventions
fludarabine phosphate
4
Cyclophosphamide
4
blinatumomab
3
Rituximab
3
Lenalidomide
2
Immunotherapy, Adoptive
2
venetoclax
1
trastuzumab deruxtecan
1
tisagenlecleucel
1
pembrolizumab
1
obinutuzumab
1
niraparib
1
nilotinib
1
isatuximab
1
acalabrutinib
1
Zymosan
1
Whole-Body Irradiation
1
Trastuzumab
1
Sodium Chloride
1
Sirolimus
1
Radiotherapy
1
Pentostatin
1
NKTR-255
1
Mycophenolic Acid
1
Melphalan
1
Magnetic Resonance Imaging
1
Immunotherapy
1
Imatinib Mesylate
1
Histamine Antagonists
1
Exercise Test
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Neoplasm, Residual
×
tisagenlecleucel
×
Clear all
NCT03876769
2026-06-02
CASSIOPEIA
Novartis
Phase 2
Active not recruiting
121 enrolled